Atrion (NASDAQ:ATRI) Downgraded to Sell at StockNews.com

StockNews.com downgraded shares of Atrion (NASDAQ:ATRI) from a hold rating to a sell rating in a report published on Tuesday.

Atrion Trading Down 0.2 %

ATRI stock opened at $462.93 on Tuesday. The business’s fifty day moving average price is $428.87 and its 200 day moving average price is $377.16. Atrion has a 12-month low of $274.98 and a 12-month high of $602.59. The company has a market capitalization of $814.76 million, a PE ratio of 43.51 and a beta of 0.62.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings results on Friday, May 10th. The medical instruments supplier reported $1.59 earnings per share (EPS) for the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%. The company had revenue of $47.33 million for the quarter.

Atrion Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Friday, June 14th will be given a dividend of $2.20 per share. This represents a $8.80 dividend on an annualized basis and a dividend yield of 1.90%. The ex-dividend date is Friday, June 14th. Atrion’s dividend payout ratio is currently 82.71%.

Hedge Funds Weigh In On Atrion

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Copeland Capital Management LLC lifted its stake in Atrion by 56.4% in the fourth quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock worth $33,000 after acquiring an additional 31 shares during the last quarter. Quadrant Capital Group LLC purchased a new stake in shares of Atrion during the 4th quarter worth $36,000. Harbor Investment Advisory LLC grew its stake in shares of Atrion by 33.1% during the fourth quarter. Harbor Investment Advisory LLC now owns 189 shares of the medical instruments supplier’s stock worth $72,000 after purchasing an additional 47 shares in the last quarter. EntryPoint Capital LLC purchased a new position in Atrion in the first quarter valued at $91,000. Finally, Tower Research Capital LLC TRC raised its stake in Atrion by 592.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock valued at $102,000 after buying an additional 231 shares in the last quarter. Hedge funds and other institutional investors own 66.19% of the company’s stock.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.